Tomoko Hata

List of Publications by Year in descending order

42 papers	258 citations	1040056 9 h-index	1058476 14 g-index
50 all docs	50 docs citations	50 times ranked	461 citing authors

#	Article	IF	Citations
1	Dasatinib-based 2-step induction for adults with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Blood Advances, 2022, 6, 624-636.	5.2	19
2	A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia. International Journal of Hematology, 2022, , 1.	1.6	1
3	Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. International Journal of Hematology, 2022, 116, 228-238.	1.6	5
4	Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy. International Journal of Hematology, 2021, 113, 765-769.	1.6	4
5	End of an Era of Sample Collection for the Nagasaki Atomic Bomb Survivor's Tumor Tissue Bank. Radiation Research, 2021, 196, 323-325.	1.5	0
6	The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience. Transplant Immunology, 2021, 67, 101417.	1.2	1
7	Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia. International Journal of Hematology, 2020, 111, 311-316.	1.6	1
8	Treatment with mogamulizumab or lenalidomide for relapsed adult Tâ€cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. Hematological Oncology, 2020, 38, 162-170.	1.7	17
9	Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome. Internal Medicine, 2020, 59, 1081-1086.	0.7	4
10	Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group. International Journal of Hematology, 2020, 112, 524-534.	1.6	1
11	No clear survival benefit of azacitidine for lowerâ€risk myelodysplastic syndromes: A retrospective study of Nagasaki. Cancer Science, 2020, 111, 4490-4499.	3.9	3
12	Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Science, 2020, 111, 1314-1323.	3.9	19
13	Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. International Journal of Hematology, 2019, 110, 654-664.	1.6	12
14	Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. International Journal of Hematology, 2019, 110, 533-542.	1.6	6
15	Complete remission of pure white cell aplasia associated with thymoma after thymectomy and cyclosporine administration. International Journal of Hematology, 2019, 109, 346-350.	1.6	8
16	Clinical features at transformation in adult T-cell leukemiaâ€“lymphoma with smoldering and chronic types. International Journal of Hematology, 2019, 109, 402-408.	1.6	5
17	Successful outcome of second allogeneic bone marrow transplantation for blastic plasmacytoid dendritic cell neoplasm with MYC locus rearrangement. Leukemia Research Reports, 2019, 11, 31-33.	0.4	3
18	Oligosecretory Primary Plasma Cell Leukemia with Atypical Morphological Abnormality. Internal Medicine, 2019, 58, 2213-2217.	0.7	1

#	Article	IF	Citations
19	EPOCH regimen as salvage therapy for adult T-cell leukemiaâ€“lymphoma. International Journal of Hematology, 2018, 108, 167-175.	1.6	4
20	Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm. International Journal of Hematology, 2018, 108, 213-217.	1.6	2
21	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. Leukemia Research, 2018, 74, 137-143.	0.8	7
22	Sweet's Syndrome in a Patient with Relapsing Polychondritis and Myelodysplastic Syndrome. Nishinihon Journal of Dermatology, 2017, 79, 19-23.	0.0	0
23	Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience. Leukemia and Lymphoma, 2016, 57, 2946-2948.	1.3	1
24	Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting. Clinica Chimica Acta, 2016, 462, 166-173.	1.1	7
25	Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. Leukemia Research, 2016, 51, 11-18.	0.8	7
26	Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki. Cancer Science, 2016, 107, 1484-1491.	3.9	9
27	Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. International Journal of Hematology, 2016, 103, 53-62.	1.6	21
28	Clonal Evolution Underlying the Progression from Myelodysplastic Syndromes to Ph-Positive Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5514-5514.	1.4	0
29	Association of Increased Ring Sideroblasts with Inferior Survival in Patients with Myelodysplastic Syndrome with Multi-Lineage Dysplasia. Blood, 2016, 128, 5530-5530.	1.4	0
30	Phase I trial of volasertib, a Poloâ€like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Cancer Science, 2015, 106, 1590-1595.	3.9	37
31	Acute Monoblastic Leukemia and Myeloproliferative Neoplasm Observed in an Elderly Man Had the Same Clonal Origin. Blood, 2015, 126, 3856-3856.	1.4	0
32	Lessons from the Atomic Bomb About Secondary MDS. Current Hematologic Malignancy Reports, 2014, 9, 407-411.	2.3	1
33	Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group. Leukemia Research, 2014, 38, 76-83.	0.8	9
34	Final Results From SENSOR: Switch to Nilotinib After Molecular Suboptimal Response (SoR) to Frontline Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2014, 124, 1815-1815.	1.4	2
35	Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes. International Journal of Hematology, 2013, 98, 687-693.	1.6	4
36	Heat Shock Protein 90 Inhibitor NVP-AUY922 Has Potent Anti-Tumor Activity With Adult T-Cell Leukemia-Lymphoma Cells. Blood, 2013, 122, 1829-1829.	1.4	3

#	Article	IF	Citations
37	Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study. Blood, 2013, 122, 2729-2729.	1.4	0
38	Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts. International Journal of Hematology, 2011, 94, 81-89.	1.6	13
39	A Clinical Pharmacology and Exploratory Study of Azacitidine Administered Subcutaneously or Intravenously In Japanese Patients with Myelodysplastic Syndrome. Blood, 2010, 116, 4964-4964.	1.4	0
40	Expression of 67-Kda Laminin Receptor (67LR) Relates to the Aggressiveness and Poor Prognosis of AML: Modulation of the Expression of GM-CSF Receptor by 67LR.. Blood, 2008, 112, 926-926.	1.4	2
41	Imatinib Provides Durable Molecular and Cytogenetic Responses in a Practical Setting for Both Newly Diagnosed and Previously Treated Chronic Myelogenous Leukemia: A Study in Nagasaki Prefecture, Japan. International Journal of Hematology, 2007, 85, 132-139.	1.6	13
42	Expression of the 67-kDa Laminin Receptor Is Associated with Increased AML Cells through the Enhanced GM-CSF/Stat5 Signaling.. Blood, 2007, 110, 2845-2845.	1.4	0